Home › Funds › TENOR CAPITAL MANAGEMENT Co., L.P. › ALNY
TENOR CAPITAL MANAGEMENT Co., L.P. position in ALNY
ALNYLAM PHARMACEUTICALS INC · Health Care
TENOR CAPITAL MANAGEMENT Co., L.P. reported holding 87,500,000 shares of ALNY (ALNYLAM PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$80.1M, representing 1.48% of its reported portfolio and ranking #10 among its reported holdings. TENOR CAPITAL MANAGEMENT Co., L.P. has disclosed ALNY holdings in 3 of the last 7 reported quarters, going back to Q1 2025.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How TENOR CAPITAL MANAGEMENT Co., L.P.'s ALNY position evolved
TENOR CAPITAL MANAGEMENT Co., L.P. first disclosed a stake in ALNY in Q1 2025 at 17,521,000 shares (US$20.24B). Across 3 filings, TENOR CAPITAL MANAGEMENT Co., L.P. increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 87,500,000 shares valued at US$80.1M. Notable position changes include a 210% increase in Q2 2025 (shares rose 40% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2025 | 17.52M | $20.24B | New |
| Q2 2025 | 54.34M | $70.93M | Add |
| Q3 2026 | 87.50M | $80.15M | New |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ALNY and 13F data
ALNY (ALNYLAM PHARMACEUTICALS INC) is a Health Care company. 30 other funds we track also report a position in ALNY — the largest reported positions include T. Rowe Price Investment Management, Inc. (US$2.47B), Baillie Gifford & Co (US$1.36B), Orbis Allan Gray Ltd (US$597.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ALNY
- T. Rowe Price Investment Management, Inc. 10.01M sh · $2.47B · Q3 2026
- Baillie Gifford & Co 5.49M sh · $1.36B · Q3 2026
- Orbis Allan Gray Ltd 2.42M sh · $597.40M · Q3 2026
- TWO SIGMA ADVISERS, LP 1.13M sh · $450.36M · Q4 2025
More on TENOR CAPITAL MANAGEMENT Co., L.P.
FAQ
How long has TENOR CAPITAL MANAGEMENT Co., L.P. held ALNY?
TENOR CAPITAL MANAGEMENT Co., L.P. has disclosed ALNY holdings in 3 of the last 7 reported quarters, going back to Q1 2025.
What is TENOR CAPITAL MANAGEMENT Co., L.P.'s current position in ALNY?
As of Q3 2026, TENOR CAPITAL MANAGEMENT Co., L.P. holds 87.50M shares of ALNY (ALNYLAM PHARMACEUTICALS INC), valued at $80.15M, representing 1.48% of its reported portfolio and ranking #10.
Has TENOR CAPITAL MANAGEMENT Co., L.P. been buying or selling ALNY?
In the latest 13F filing (Q3 2026), TENOR CAPITAL MANAGEMENT Co., L.P. newly opened its position in ALNY.
Which other funds hold ALNY?
Other major institutional holders of ALNY include T. Rowe Price Investment Management, Inc., Baillie Gifford & Co, Orbis Allan Gray Ltd, among 30 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.